Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exelixis

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

StockNews.com

Exelixis Stock Sees Rising Relative Strength Rating

Exelixis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 87.

Investors Business Daily

Exelixis Stock Flashes Improved Relative Price Strength With Upgrade

Exelixis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark

A Relative Strength Rating upgrade for Exelixis shows improving technical performance. Will it continue?

Investors Business Daily

Exelixis Stock Shows Market Leadership, Earns 81 RS Rating

Exelixis sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Exelixis Stock Generating Improved Relative Strength Rating

A Relative Strength Rating upgrade for Exelixis shows improving technical performance. Will it continue?

Investors Business Daily

Dow Jones Futures: Inflation Report Looms For Market Rally; Twitter Rallies As Elon Musk Sells More Tesla Stock

July's CPI inflation report is due for the market rally. Elon Musk sold $6.9 billion of Tesla stock as Twitter deal odds rise. TSLA and TWTR rose.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Exelixis Stock Undercuts Key Line As Guidance Drags On Quarterly Beat

Exelixis easily beat second-quarter expectations, but kept its 2022 outlook and EXEL stock crumbled Wednesday.

Investors Business Daily

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Exelixis Stock Flashing Renewed Technical Strength, Hitting RS Of 90

Exelixis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Exelixis-BioInvent Establish Immuno-Oncology Pact

Exelixis Inc (NASDAQ:EXEL) and BioInvent International AB (OTC:BOVNF) have entered into an option and license agreement focused on identifying and developing novel antibodies for use in immuno-oncology therapeutics. Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets identified using BioInvent's proprietary F.I.R.S.T platform and n-CoDeR library. …

Benzinga

Exelixis: Q1 Earnings Insights

Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 85.71%, reporting an EPS of $0.26 versus an estimate of $0.14.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Stock Of The Day: Exelixis And The Next Opportunity To Spark Shares

Exelixis is the IBD Stock Of The Day as it adds onto a lengthy consolidation ahead of a key test for its headliner cancer treatment.

Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC).

StockNews.com

4 Outperforming Growth Stocks to Buy in March

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FICO), Ralph Lauren (RL), and Exelixis (EXEL), which have outpaced the broader…

StockNews.com

2 Undervalued Biopharmaceutical Stocks to Scoop Up in February

Biopharma stocks have been trading at lower valuations because of uncertainties surrounding drug-pricing reform, regulatory surprises, and COVID-19. However, the biopharma industry is expected to grow in the coming years. Given the bullish analysts’ sentiment around the sector, biopharma stocks Gilead (GILD) and Exelixis (EXEL), which look undervalued at their…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Exelixis: Q4 Earnings Insights

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 483.33%, reporting an EPS of $0.35 versus an estimate of $0.06.

Benzinga

Earnings Preview For Exelixis

Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will report an earnings per share (EPS) of $0.06.

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.